Details

Autor(en) / Beteiligte

• Arakelyan, Nina
• Jais, Jean-Philippe
• Tomowiack, Cécile
• Colombat, Philippe
• Berthou, Christian
• Desablens, Bernard
• Moles-Moreau, Marie-Pierre
• Gastinne, Thomas
• Quittet, Philippe
• Casassus, Philippe
• Le Pourhiet-Le Mevel, Annick
• Ghandour, Christiane
• Brière, Josette
• Colonna, Pierre
• Andrieu, Jean-Marie

Titel

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation

Ist Teil von

• Leukemia & lymphoma, 2013-01, Vol.54 (1), p.76-82

Ort / Verlag

United States: Informa Healthcare

Erscheinungsjahr

2013

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• The H97-I trial (1997-2004) for Hodgkin lymphoma at intermediate stage (HL-I) included 269 patients who were randomized to receive three or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 197 patients who reached complete remission (CR) (73.2%, p = 0.41 between arms) received radiotherapy (RT); their 10-year progression-free survival (PFS) rate was 87.7 ± 3.0%, similar to that of the 180 patients of a historical control group (HCG) in CR after three ABVD cycles before RT. The 59 patients who reached post-ABVD partial remission (PR) received one course of intensive chemotherapy (i.v., mg/m2, vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before RT. In spite of this additional intensive chemotherapy, their PFS rate (78.4 ± 6.3%) remained significantly lower (p = 0.03) than that of the 197 patients who reached post-ABVD CR, and was similar to that of the 60 patients of the HCG in PR after three ABVD cycles who did not receive additional chemotherapy before RT.